suramin has been researched along with Germinoma in 1 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Germinoma: A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
Excerpt | Relevance | Reference |
---|---|---|
"Based on these data, the effects of suramin were studied on the growth of a monolayer culture of two human teratocarcinoma cell lines, NT2/D1 and N2102ep." | 5.07 | Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. ( Bajorin, DF; Bost, GJ; Dmitrovsky, E; Miller, WH; Motzer, RJ; Scher, HI; Tong, WP, 1993) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Motzer, RJ | 1 |
Dmitrovsky, E | 1 |
Miller, WH | 1 |
Tong, WP | 1 |
Bajorin, DF | 1 |
Scher, HI | 1 |
Bost, GJ | 1 |
1 trial available for suramin and Germinoma
Article | Year |
---|---|
Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial.
Topics: Adult; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance; Female; Germinoma; Humans; Infu | 1993 |